IntAct European Bioinformatics Institute IntAct intact http://www.ebi.ac.uk/ http://www.ebi.ac.uk/intact/query/${ac} EBI-[0-9]+|IA:[0-9]+ INTerAction database (IntAct) provides an open source database and toolkit for the storage, presentation and analysis of molecular interactions. http://www.ebi.ac.uk/intact European Bioinformatics Institute; Wellcome Trust Genome Campus; Hinxton, Cambridge; CB10 1SD; United Kingdom http://www.ebi.ac.uk/intact/ Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Nature communications 2020 imex curation Lee J., Worrall LJ., Vuckovic M., Rosell FI., Gentile F., Ton AT., Caveney NA., Ban F., Cherkasov A., Paetzel M., Strynadka NCJ. Virus - Publications including interactions involving viral proteins Coronavirus - Interactions investigated in the context of Coronavirus mpaetzel@sfu.ca, ncjs@mail.ubc.ca 29-Mar-2021: Contacted by IntAct-Help. Only protein-protein interactions imex curation in vitro In vitro cleavage cleavage assay cleavage predetermined predetermined participant predetermined Lee J., Worrall LJ., Vuckovic M., Rosell FI., Gentile F., Ton AT., Caveney NA., Ban F., Cherkasov A., Paetzel M., Strynadka NCJ. Virus - Publications including interactions involving viral proteins FRET based assay:On cleavage of the peptide by the protease, the quencher (DNP) and fluorophore (MCA) are separated giving a large increase in fluorescence. mpaetzel@sfu.ca, ncjs@mail.ubc.ca Accepted 2021-JAN-24 AT 15:12 GMT AT 15:12 GMT by KALPANAP Nature communications 2020 Only protein-protein interactions imex curation imex curation Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Nature communications 2020 imex curation Lee J., Worrall LJ., Vuckovic M., Rosell FI., Gentile F., Ton AT., Caveney NA., Ban F., Cherkasov A., Paetzel M., Strynadka NCJ. Virus - Publications including interactions involving viral proteins Coronavirus - Interactions investigated in the context of Coronavirus mpaetzel@sfu.ca, ncjs@mail.ubc.ca 29-Mar-2021: Contacted by IntAct-Help. Only protein-protein interactions imex curation ecoli Escherichia coli (strain K12) saxs x ray scattering saxs predetermined predetermined participant predetermined Lee J., Worrall LJ., Vuckovic M., Rosell FI., Gentile F., Ton AT., Caveney NA., Ban F., Cherkasov A., Paetzel M., Strynadka NCJ. Virus - Publications including interactions involving viral proteins mpaetzel@sfu.ca, ncjs@mail.ubc.ca Accepted 2021-JAN-24 AT 15:12 GMT AT 15:12 GMT by KALPANAP Nature communications 2020 Only protein-protein interactions imex curation imex curation Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Nature communications 2020 imex curation Lee J., Worrall LJ., Vuckovic M., Rosell FI., Gentile F., Ton AT., Caveney NA., Ban F., Cherkasov A., Paetzel M., Strynadka NCJ. Virus - Publications including interactions involving viral proteins Coronavirus - Interactions investigated in the context of Coronavirus mpaetzel@sfu.ca, ncjs@mail.ubc.ca 29-Mar-2021: Contacted by IntAct-Help. Only protein-protein interactions imex curation ecoli Escherichia coli (strain K12) molecular sieving molecular sieving Gel Filtration Size Exclusion Chromatography Size Exclusion Chromatography Gel Filtration Sizing column predetermined predetermined participant predetermined Lee J., Worrall LJ., Vuckovic M., Rosell FI., Gentile F., Ton AT., Caveney NA., Ban F., Cherkasov A., Paetzel M., Strynadka NCJ. Virus - Publications including interactions involving viral proteins mpaetzel@sfu.ca, ncjs@mail.ubc.ca Accepted 2021-JAN-24 AT 15:12 GMT AT 15:12 GMT by KALPANAP Nature communications 2020 Only protein-protein interactions imex curation imex curation Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Nature communications 2020 imex curation Lee J., Worrall LJ., Vuckovic M., Rosell FI., Gentile F., Ton AT., Caveney NA., Ban F., Cherkasov A., Paetzel M., Strynadka NCJ. Virus - Publications including interactions involving viral proteins Coronavirus - Interactions investigated in the context of Coronavirus mpaetzel@sfu.ca, ncjs@mail.ubc.ca 29-Mar-2021: Contacted by IntAct-Help. Only protein-protein interactions imex curation ecoli Escherichia coli (strain K12) x-ray diffraction x-ray crystallography X-ray X-ray x-ray diffraction predetermined predetermined participant predetermined Lee J., Worrall LJ., Vuckovic M., Rosell FI., Gentile F., Ton AT., Caveney NA., Ban F., Cherkasov A., Paetzel M., Strynadka NCJ. Virus - Publications including interactions involving viral proteins mpaetzel@sfu.ca, ncjs@mail.ubc.ca Accepted 2021-JAN-24 AT 15:12 GMT AT 15:12 GMT by KALPANAP Nature communications 2020 Only protein-protein interactions imex curation imex curation p0dtd1-pro_0000449623 3C-like proteinase nsp5 rep ORF1ab polyprotein 1a-1b protein protein SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 2019-nCoV SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIRKSNHNFLVQAGNVQLRVIGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGNFYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQ 3264 3569 carmofur Carmofur 1-hexylcarbamoyl-5-fluorouracil Carmofur mifurol yamaful small molecule small molecule chemical synthesis Chemical synthesis (Chemical synthesis) mca-avlqsgfr-lys(dnp)-lys-nh2 MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 peptide peptide polypeptide oligopeptide oligopeptide polypeptide chemical synthesis Chemical synthesis (Chemical synthesis) AVLQSGFR rep-144 4 5 unspecified role unspecified role neutral component neutral component purified purified direct interaction direct interaction Supp. Table 1 rep-145 4 5 unspecified role unspecified role neutral component neutral component purified purified P0DTD1-PRO_0000449623:p.Cys145Ala mutation mutation certain certain sequence position certain certain certain sequence position certain C A Sun Dec 13 19:41:19 GMT 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p0dtd1-pro_0000449623:p.Cys145Ala' direct interaction direct interaction Supp. Table 1 rep-146 2 5 unspecified role unspecified role neutral component neutral component purified purified P0DTD1-PRO_0000449623:p.Pro9Thr mutation disrupting strength mutation disrupting interaction strength mutation disrupting strength certain certain sequence position certain certain certain sequence position certain P T Sun Dec 13 19:47:42 GMT 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p0dtd1-pro_0000449623:p.Pro9Thr' direct interaction direct interaction Supp. Table 2, Supp. figure 2 rep-147 3 5 unspecified role unspecified role neutral component neutral component purified purified P0DTD1-PRO_0000449623:p.Pro9Thr mutation decreasing strength mutation decreasing interaction strength mutation decreasing strength certain certain sequence position certain certain certain sequence position certain P T Sun Dec 13 18:32:29 GMT 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p0dtd1-pro_0000449623:p.Pro9Thr' direct interaction direct interaction Supp. figure 3 mca_avlqsgfr_lys(dnp)_lys_nh2-rep-3 1 5 enzyme enzyme neutral component neutral component purified purified P0DTD1-PRO_0000449623:p.Pro9Thr mutation disrupting rate mutation disrupting interaction rate mutation disrupting rate certain certain sequence position certain certain certain sequence position certain P T Sun Dec 13 18:40:11 GMT 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p0dtd1-pro_0000449623:p.Pro9Thr' ecoli Escherichia coli (strain K12) 7 enzyme target enzyme target substrate substrate neutral component neutral component n-terminus fluorophore fluorophore n-term range n-terminal range n-term range n-term range n-terminal range n-term range chemical synthesis Chemical synthesis (Chemical synthesis) cleavage cleavage reaction cleavage Supp. figure 4 Hill coefficient =~1.7 for Wild type and mutant. carmofur-mca_avlqsgfr_lys(dnp)_lys_nh2-1 1 6 inhibitor inhibitor neutral component neutral component chemical synthesis Chemical synthesis (Chemical synthesis) 5 enzyme enzyme neutral component neutral component purified purified ecoli Escherichia coli (strain K12) 7 enzyme target enzyme target substrate substrate neutral component neutral component n-terminus fluorophore fluorophore n-term range n-terminal range n-term range n-term range n-terminal range n-term range chemical synthesis Chemical synthesis (Chemical synthesis) cleavage cleavage reaction cleavage Supp. figure 4